New Data Highlights the Value of SPRAVATO ™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[i]
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 22, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA Grants Priority Review of INVOKANA ® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 22, 2019 Category: Pharmaceuticals Source Type: news

New Real-World Evidence Highlights Need for Interventions to Improve Outcomes for Patients Who Have Been Diagnosed with Major Depressive Disorder (MDD) and Suicide Ideation or Attempt
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 21, 2019 Category: Pharmaceuticals Source Type: news

Auris Health Announces Early Results from First-In-Human Study of Monarch ™ Platform
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 21, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in Bernstein's 35th Annual Strategic Decisions Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 17, 2019 Category: Pharmaceuticals Source Type: news

Janssen to Present Data from Robust Oncology Portfolio and Pipeline at the 2019 ASCO Annual Meeting, Including Best of ASCO Selections
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 16, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 15, 2019 Category: Pharmaceuticals Source Type: news

Janssen Demonstrates Strong Commitment to Inflammatory Bowel Disease with Data from 25 Abstracts Presented at the 2019 Digestive Disease Week Annual Meeting
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 14, 2019 Category: Pharmaceuticals Source Type: news

New Study Finds Chronic Kidney Disease Remains Largely Undiagnosed in Nearly Half of Patients with Type 2 Diabetes and Chronic Kidney Disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 10, 2019 Category: Pharmaceuticals Source Type: news

The Cost of Complacency: Economist Intelligence Unit Report Underscores Major Gaps in World ’s Response to Drug-Resistant Tuberculosis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 7, 2019 Category: Pharmaceuticals Source Type: news

Health Systems Can Address Clinician Burnout and Increase Employee Engagement with the Help of Healthy Workforce Offerings from the Johnson & Johnson Medical Devices Companies
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 6, 2019 Category: Pharmaceuticals Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA ® (apalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 29, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces Submission of New Drug Application to U.S. FDA For the First Monthly, Injectable, Two-Drug Regimen of Rilpivirine and Cabotegravir for Treatment of HIV
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 29, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Dividend Increase of 5.6%
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 25, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Host Pharmaceutical Business Review
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 25, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2019 First-Quarter Results:
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 16, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces Investigational CAR-T Therapy JNJ-68284528 Granted PRIME Designation by the European Medicines Agency
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 15, 2019 Category: Pharmaceuticals Source Type: news

BALVERSA ™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 15, 2019 Category: Pharmaceuticals Source Type: news

INVOKANA ® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 15, 2019 Category: Pharmaceuticals Source Type: news

Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA ® through 48 Weeks
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 11, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Winners of 2019 Women in STEM2D Scholars Award
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 10, 2019 Category: Pharmaceuticals Source Type: news

New Pediatric Formulation of Janssen ’s Treatment for Intestinal Worms Achieves World Health Organization Prequalification
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 9, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Completes Divestiture of Advanced Sterilization Products (ASP) to Fortive Corporation
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 1, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Completion of Acquisition of Auris Health, Inc.
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 1, 2019 Category: Pharmaceuticals Source Type: news

Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA ® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 28, 2019 Category: Pharmaceuticals Source Type: news

Janssen Submits Application for DARZALEX ® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 26, 2019 Category: Pharmaceuticals Source Type: news

Ethicon Launches Global Registry to Collect Real-World Data on Liver Lesions Ablated with The Neuwave Microwave Ablation System
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 25, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Joins Forces with Monash University-led Partnership to Advance Novel Technology Aimed at Saving Lives of Women in Child Birth
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 21, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to HostInvestor Conference Call on First-Quarter Results
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 19, 2019 Category: Pharmaceuticals Source Type: news

XARELTO ® (rivaroxaban) Significantly Reduced the Risk of Overall Strokes and the Most Severe Strokes and Was Associated with Fewer Stroke-Related Deaths in the Real World Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 18, 2019 Category: Pharmaceuticals Source Type: news

Interim Analysis Showed Treatment with OPSUMIT ® (macitentan) Associated with Significant Improvement in Right Ventricular (RV) Function and Pulmonary Vascular Resistance (PVR) in Patients with Pulmonary Arterial Hypertension (PAH)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 15, 2019 Category: Pharmaceuticals Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX ® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 12, 2019 Category: Pharmaceuticals Source Type: news

XARELTO ® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 11, 2019 Category: Pharmaceuticals Source Type: news

New Phase 3 Stelara ® (Ustekinumab) Data Show Positive Results as Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 11, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of SPRAVATOTM (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 6, 2019 Category: Pharmaceuticals Source Type: news

New Global Headquarters for Johnson & Johnson Human Performance Institute ® Reimagines Workplace Wellbeing
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 5, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Consumer Highlights Innovation in Skin Science at 2019 American Academy of Dermatology Annual Meeting
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 1, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in Barclays Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 28, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of Novel TREMFYA ® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 27, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Innovation Names Winners of Inaugural Champions of Science – Africa Storytelling Challenge
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 15, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 14, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 14, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 13, 2019 Category: Pharmaceuticals Source Type: news

FDA Advisory Committee Recommends Approval of SPRAVATOTM (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 12, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves DARZALEX ® (daratumumab) Split-Dosing Regimen
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 12, 2019 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Participate in the 2019 CAGNY Conference
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 5, 2019 Category: Pharmaceuticals Source Type: news

First Atrial Fibrillation Patient Treated in Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation Catheter
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 5, 2019 Category: Pharmaceuticals Source Type: news

Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 31, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces ERLEADA ® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 30, 2019 Category: Pharmaceuticals Source Type: news

New Study Suggests Surgical Stapler May Play Important Role in Reducing Common Complications Associated with Lung Surgery
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 28, 2019 Category: Pharmaceuticals Source Type: news